太阳集团tyc(中国)

Be the most trusted biotech company

2025-07-02

Henlius Receives New EMA GMP Certification, Accelerating European Market Entry of Two Biosimilar Candidates
2025-07-02

Henlius and HanchorBio Collaborate to Develop Novel SIRPα-Fc Fusion Protein, Expanding Tumor Immunotherapy Layout
2025-06-26

Henlius Hosts Investigator Meeting for Bridging Study of Serplulimab in Japan
2025-06-25

Henlius Doses First Patient in Japanese Bridging Study of Serplulimab for Extensive-Stage Small Cell Lung Cancer
2025-06-24

Serplulimab Approved in the UK and India for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
2025-06-20

Henlius Shines at 2025 BIO International Convention, Showcasing Its Innovative Achievements
2025-06-13

Expanding Southeast Asian Presence: Serplulimab Approved in Singapore and Malaysia
2025-06-10

First Subject Dosed for a Phase 2 MRCT of Henlius’ PD-L1-Targeting ADC HLX43 for the Treatment of NSCLC
2025-06-09

Henlius Showcases Global Innovation Momentum at Jefferies Global Healthcare Conference 2025